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The release of norepinephrine (NE) from sympathetic nerves in the heart is regulated by several pre-synaptic receptors (Boehm and Kubista, 2002) . Of these, some are inhibitory (e.g., α 2 -adrenergic, adenosine A 1 and histamine H 3 receptors) (Imamura et al., 1996) and others, facilitatory (e.g., angiotensin AT 1 and purinergic P2X receptors; P2XR) (Seyedi et al., 1997; Sesti et al., 2002; Seyedi et al., 2002) . Each of these receptors can be activated in an autocrine or paracrine mode by the respective endogenous ligand. Local concentrations of the ligand are reduced by reuptake into nerve endings or by metabolic hydrolysis, as in the case of NE (Amara and Kuhar, 1993) and ATP (Zimmermann and Braun, 1999) , respectively.
We recently reported that ATP, co-released with NE from cardiac sympathetic nerve terminals, increases NE release via a positive feedback mechanism (Sesti et al., 2002) . Furthermore, an endogenous ectonucleotidase (E-NTPDase), which we identified in cardiac sympathetic nerve endings, metabolically deletes released ATP, thereby effectively decreasing NE release (Sesti et al., 2002) . Inasmuch as excessive NE release in hyperadrenergic states, such as acute myocardial ischemia, can further exacerbate cardiac dysfunction (Levi and Smith, 2000) , we studied whether the ATP-mediated autocrine positive feedback amplification of NE This article has not been copyedited and formatted. The final version may differ from this version. To this end, we chose the isolated, spontaneously beating heart, subjected to either 10-or 20-min periods of ischemia, as the experimental model. In these two time frames, NE is released by exocytosis and reversal of the NE transporter, respectively (Hatta et al., 1999) . Further, to eliminate possible effects of ATP produced by myocytes and endothelial cells, and to restrict the role of E-NTPDase to transmitter ATP released from sympathetic terminals, we isolated sympathetic nerve endings from the heart (cardiac synaptosomes) and subjected them to progressively increasing periods of ischemia. We report here that in short-term ischemia, characterized by exocytosis of NE and ATP, E-NTPDase limits the availability of released ATP at sympathetic nerve terminals. We conclude that E-NTPDase modulates the P2XR-mediated, positive feedback mechanism that exacerbates ischemic NE release.
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Materials and Methods

Preparation of Cardiac Synaptosomes
Male Hartley guinea pigs (250-300 g) were sacrificed by cervical dislocation under light anesthesia with CO 2 vapor in accordance with Institutional guidelines. The rib cage was dissected away, and the heart rapidly excised, freed from fat and connective tissue, and transferred to a Langendorff apparatus. Spontaneously beating hearts were perfused through the aorta for 15 min at constant pressure (40 cm of H 2 O) with Ringer's solution at 37°C saturated with 100% O 2 (pH 7.5) (Seyedi et al., 1997 ). This procedure ensured that blood did not remain in the coronary circulation. At the end of perfusion, the hearts were minced in ice-cold 0.32 M sucrose containing 1 mM EGTA, pH 7.4. The minced tissue was digested with 40 mg collagenase per 10 ml of HEPES-buffered saline solution (HBS) per gram of wet heart weight for 45 min at 37°C. HBS contained 50 mM HEPES, pH 7.4, 144 mM NaCl, 5 mM KCl, 1.2 mM CaCl 2 , 1.2 mM MgCl 2 , 10 mM glucose and 1 mM pargyline (monoamine oxidase inhibitor) to prevent enzymatic degradation of synaptosomal NE (Seyedi et al., 1997) . After low-speed centrifugation (10 min, 120 g, 4°C), the resulting pellet was suspended in 10 volumes of 0.32 M sucrose and homogenized with a Teflon/glass homogenizer. The homogenate was centrifuged (10 min, 650 g, 4°C) and the pellet re-homogenized and reThis article has not been copyedited and formatted. The final version may differ from this version. Each pellet, containing cardiac synaptosomes, was resuspended either in HBS pH 7.4 (normoxic conditions) or in glucose-free HBS, containing the reducing agent sodium dithionite (ischemic conditions) to a final volume of 0.5 ml in the presence or absence of drugs. Each suspension was incubated in a water bath at 37°C either in the absence or presence of the NE transporter inhibitor desipramine (DMI); a recombinant soluble form of human E-NTPDase1/CD39 (solCD39) (Gayle, III et al., 1998) ; the ENTPDase inhibitor, 6-N,N-diethyl-β-γ-dibromomethylene-D-adenosine-5'-triphosphate (ARL67156) and the P2XR antagonist, pyridoxal-phosphate-6-azophenyl-2',4'-disulphonic acid (PPADS). These agents were added at the concentrations indicated, 5 min prior to ischemia or normoxia. In each experiment, one sample was untreated (control, basal NE release) and incubated for the same length of time under both conditions.
Induction of Ischemia in Cardiac Synaptosomes
Ischemia was induced by incubating synaptosomes for 10, 20, 30 or 70 min in glucose-free HBS bubbled with 95% N 2 and 5% CO 2 , containing sodium dithionite (3 mM, PO 2 ~0 mmHg, pH ~7.3; ischemic release) (Seyedi et al., 2002) . Matched synaptosomes were incubated for This article has not been copyedited and formatted. The final version may differ from this version. Following incubation, each sample was centrifuged (20 min, 20,000 g, 4°C) and the supernatant assayed either for NE content by highperformance liquid chromatography with electrochemical detection (Seyedi et al., 1997) or ATP content by luciferin-luciferase luminometry (see below). The pellet was assayed for protein content by a modified Lowry procedure (Seyedi et al., 1997) . Data were expressed as pmol/mg protein for NE and fmol/mg protein for ATP (mean ± S.E.M.; n = number of observations).
Ischemia/Reperfusion in Isolated Hearts
Guinea-pig hearts were isolated as described above and perfused for 30-min (stabilization period) prior to ischemia. Normothermic 10-min or 20-min global ischemia was then induced by complete cessation of coronary perfusion, followed by a 20-min reperfusion period (Hatta et al., 1999) . The coronary effluent was collected into tubes, every 5 min for a total of 15 min, prior to ischemia and every 2 min following ischemia. When DMI, solCD39, ARL67156 or PPADS was used, the heart was perfused with the compound for the duration of the experiment. Hearts were weighed at the end of the experiment. Samples of coronary effluent were assayed for NE and ATP, by HPLC with electrochemical detection and 
Radio-TLC Assay for E-NTPDase activity
Exogenous ATP was added to samples of synaptosomes or solCD39
and its metabolism was measured. (Drosopoulos et al., 2000; Sesti et al., 2002) . Values were calculated as averages of triplicate measurements following subtraction of buffer blanks (consistently less than 1% of total radioactivity). Data were expressed as percentage of ATP metabolized.
Chemicals and Drugs
SolCD39 was a generous gift from Drs. C.R. Maliszewski and R.B.
Gayle, III (Immunex Corp, Seattle, WA). All other chemicals were purchased from Sigma-Aldrich, St. Louis, MO.
Statistical Analysis
Statistical analysis was performed using GraphPad Software (Prism 3.00 and InStat 3.01). Statistical comparisons between groups were made by one-way ANOVA followed by post-test analysis with the methods of Bonferroni (isolated hearts) and Tukey (synaptosomes).
Results
Overflow of NE and ATP at reperfusion following 10-minute ischemia in guinea-pig hearts.
NE overflow into the coronary effluent of isolated guinea-pig hearts during 20-min reperfusion, following a 10-min period of global ischemia, increased from an undetectable pre-ischemic level to 4.52 ± 0.37 pmol/g (± S.E.M.; n = 6) ( Fig. 1A ). In the presence of the NE transporter inhibitor DMI (300 nM), NE overflow after ischemia was further increased by ~50%,
indicating that the increase in NE overflow resulted from exocytotic NE release. When hearts were perfused with the P2XR antagonist PPADS (30Ã M), NE overflow after ischemia was reduced by ~43%. NE overflow was also reduced (~45%) in the presence of the recombinant soluble form of human E-NTPDase1/CD39, solCD39 (10 nM). Perfusion with the ENTPDase inhibitor ARL67156 (30 µM) elicited a ~43% increase in NE overflow, whereas ARL67156 and PPADS in combination decreased NE overflow by ~35% (Fig. 1A ).
ATP overflow into the coronary effluent of the same guinea-pig hearts increased three fold from a pre-ischemic level of 10.93 ± 1.70 to a post-ischemic level of 29.67 ± 1.29 pmol/g (± S.E.M.; n = 6) ( ischemic levels. In hearts perfused with solCD39, ATP overflow was undetectable both before and after ischemia.
Overflow of NE and ATP at reperfusion following 20-minute ischemia in guinea-pig hearts.
NE overflow into the coronary effluent of isolated guinea-pig hearts during 20-minute reperfusion, following a 20-minute period of global ischemia, increased from an undetectable pre-ischemic level to 608.50 ± 39.62 pmol/g (± S.E.M.; n = 6) ( Fig. 2A ). In the presence of the NE transporter inhibitor DMI (300 nM), NE overflow after ischemia was decreased by ~84%. This indicated that the increase in NE overflow resulted from carrier-mediated NE release, due to reversal of the NE transporter. In contrast, when hearts were perfused either with the P2XR antagonist PPADS (30Ã M), or with the recombinant soluble form of human E-NTPDase1/CD39, solCD39 (10 nM), or with the E-NTPDase inhibitor ARL67156 (30 µM), NE overflow after ischemia was the same as in the absence of these agents ( Fig. 2A) .
ATP overflow into the coronary effluent of the same guinea-pig hearts increased 2-fold from a pre-ischemic level of 11.70 ± 0.20 to a postischemic level of 24.25 ± 0.21 pmol/g (± S.E.M.; n = 6) ( Fig. 2B ). In the presence of PPADS or ARL67156, ATP overflow after ischemia increased 3-fold from the respective pre-ischemic levels. In hearts perfused with solCD39, ATP overflow was undetectable both before and after ischemia.
Shown in figure 3 is the lack of correlation between the overflow of ATP and that of NE in 30 and 24 guinea-pig hearts subjected to 10-(panel A) and 20-min ischemia (panel B), respectively, both in the absence and in the presence of PPADS, ARL67156 and solCD39.
NE and ATP release from ischemic cardiac sympathetic nerve terminals.
Sympathetic nerve terminals (cardiac synaptosomes) were isolated from guinea-pig hearts and incubated for 10, 20, 30 and 70 minutes, either under normoxic or ischemic conditions (see Methods). Ischemia caused a marked increase in NE and ATP release, in the picomolar and femtomolar range, respectively. NE release progressively increased with the time of exposure to ischemia, while the increase in ATP release progressively declined (Fig. 4) . In the presence of the NE transporter inhibitor DMI (300 nM), NE release was enhanced by ~35% after 10-min ischemia but was reduced by ~65% after 30-min ischemia (Figs. 5A and 7A). This indicated that NE release was exocytotic during the first 10 minutes of ischemia and carrier-mediated, due to reversal of the NE transporter, in the subsequent 20 minutes. In contrast, DMI had no effect on ATP release (Figs. 5B and 7B).
This article has not been copyedited and formatted. The final version may differ from this version. Exocytotic release of NE and ATP from cardiac synaptosomes during 10-min ischemia.
Incubation of cardiac synaptosomes for 10 minutes under ischemic conditions elicited a ~64% increase in the release of NE above basal normoxic conditions. This increase was reduced by ~40% by the P2XR
antagonist PPADS (10 M) or by the recombinant soluble form of human E-NTPDase1/CD39, solCD39 (3 nM). In contrast, the E-NTPDase inhibitor ARL67156 (30 µM) potentiated by ~50% the increase in NE release caused by 10-min ischemia. When ARL67156 and PPADS were used in combination, the ischemia-induced increase in NE release was attenuated by ~40% (Fig. 5A ).
In the same synaptosomes, a 10-min period of ischemia elicited a 4-fold increase in ATP release above the normoxic state. This increase was reduced by ~50% in the presence of PPADS, and was completely suppressed by solCD39. In contrast, the increase in ATP release induced by 10-min ischemia was further potentiated by 2.5-fold in the presence of ARL67156. When ARL67156 and PPADS were used in combination, the ischemia-induced increase in ATP release was attenuated by ~40% (Fig.   5B ). In normoxic conditions, DMI, PPADS, ARL67156 and solCD39 had no effect on NE and ATP release. Shown in Figure 6 is the correlation between the release of ATP and that of NE from synaptosomes isolated from 16 guinea-pig hearts and subjected to 10-min ischemia, either in the absence or presence of various drugs. NE release was directly correlated with ATP release (r 2 =0.843).
Notably, agents that decreased (PPADS, solCD39, ARL67156+PPADS) or increased (ARL67156) ATP release also decreased or increased NE release.
Release of NE and ATP from cardiac synaptosomes during 30-min ischemia.
Incubation of cardiac synaptosomes for 30 minutes under ischemic conditions elicited a ~2-fold increase in NE release above baseline normoxic conditions. This increase was inhibited by ~15% in the presence of either PPADS (10 µM), solCD39 (3 nM), or PPADS and ARL67156 in combination. In contrast, ARL67156 (30 µM) potentiated the ischemiainduced increase in NE release by ~17% (Fig. 7A ).
In these synaptosomes, 30-min of ischemia elicited a 2.5-fold increase in ATP release above the normoxic state. This increase was reduced by ~30% in the presence of PPADS and was completely suppressed by solCD39. In contrast, ARL67156 elicited a ~6-fold increase in ischemia-induced ATP release. When ARL67156 and PPADS were used in combination, the increase in ATP release was attenuated by ~45%
This article has not been copyedited and formatted. The final version may differ from this version. (Fig. 7B) . In normoxic conditions, DMI, PPADS, ARL67156 and solCD39 had no effect on NE and ATP release. There was no correlation between ATP and NE release (data not shown).
Effects of PPADS on E-NTPDase activity.
Although PPADS is classified as a selective P2XR antagonist ( 
Discussion
We previously reported the presence of ecto-nucleotidase (ENTPDase) activity in cardiac sympathetic nerve terminals (Sesti et al., 2002) . We determined how this ecto-nucleotidase, by hydrolyzing ATP released from the nerves, reduced the availability of ATP at presynaptic ionotropic P2XR that facilitate NE release. Thus, we demonstrated that a function of this ecto-nucleotidase was to attenuate NE exocytosis from cardiac sympathetic nerve endings (Sesti et al., 2002) . These studies have now been extended to ecto-nucleotidase in ischemia-reperfusion models in the whole heart and in sympathetic nerve endings. In these models, NE release can be either exocytotic, or carrier-mediated, due to reversal of the NE transporter (Hatta et al., 1999) .
In short-term ischemia models, in both the isolated heart and cardiac synaptosomes, NE exocytosis was augmented by inhibition of E-NTPDase with ARL67156. Moreover, NE exocytosis was markedly reduced either by enhancing the hydrolysis of released ATP with solCD39, or by blocking P2XR with PPADS. Interestingly, when ARL67156 was combined with PPADS, the blockade of P2XR prevented ARL67156-induced potentiation of NE release. Collectively, these findings support the concept that ATP, released from sympathetic nerve endings in the heart, activates prejunctional P2XR in an autocrine mode. This positive feedback mechanism amplifies NE exocytosis not only in physiological, but also in In our long-lasting ischemia models, both in the isolated heart and in cardiac synaptosomes, released ATP did not modulate NE release. In these models, NE release is mainly carrier-mediated and Ca 2+ -independent; i.e., NE is "carried" out of sympathetic nerve endings via the NE transporter operating in an outward direction (Hatta et al., 1999; Seyedi et al., 2002) . This occurs because, with prolonged ischemia, the intra- therefore, the release of transmitter ATP can only be exocytotic (von Kugelgen et al., 1994; Bodin and Burnstock, 2001) . In fact, the release of ATP elicited by ischemia did not increase like that of NE, but actually diminished with time, reflecting the progressive loss of exocytosis. Indeed, we found that the promotion of NE release by co-released ATP and its modulation by neuronal ecto-nucleotidase, which were very evident in cardiac synaptosomes after 10 min of ischemia, were greatly diminished after 20 additional minutes of ischemia. In conclusion, our findings support a key role for neuronal ENTPDase in the control of adrenergic function in the ischemic heart. We demonstrate that by limiting the availability of released ATP at sympathetic nerve terminals, E-NTPDase modulates the P2XR-mediated, positive feedback mechanism that enhances NE and ATP release. Enhanced adrenergic activity and excessive NE release are known causes of clinical cardiac dysfunction in myocardial ischemia (Braunwald and Sobel, 1988; Dart and Du, 1993; Kübler and Strasser, 1994; Benedict et al., 1996) . Therefore, our results identify a protective role for the E-NTPDase at cardiac sympathetic nerve terminals and suggest that by mitigating ATPmediated NE release, solCD39 may offer a novel therapeutic approach to myocardial ischemia and its consequences. Moreover, solCD39 strongly inhibits human platelet aggregation induced by ADP, collagen, arachidonate, or TRAP (thrombin receptor agonist peptide) (Marcus et al., 2003) . In a murine model of stroke, driven by excessive platelet recruitment, solCD39 reduced the sequelae of stroke, without an increase in intracerebral hemorrhage (Pinsky et al., 2002) . Thus, in the heart, solCD39 has the potential not only of attenuating NE release and its dysfunctional consequences, but also of impeding the transition from myocardial ischemia to infarction.
This article has not been copyedited and formatted. The final version may differ from this version. observations. In all likelihood, the lack of correlation reflected a greatly increased ATP production in the whole heart by cellular sources other than sympathetic nerve terminals (see Discussion).
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